ClinicalTrials.gg
Not yet recruitingNCT07606976Updated May 26, 2026

A Study of SSS68 Following a Single Subcutaneous Administration in Healthy Adult Participants

A Phase 1 interventional study of SSS68 and Placebo in Healthy, sponsored by Shenyang Sunshine Pharmaceutical Co., LTD.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Shenyang Sunshine Pharmaceutical Co., LTD. (part of 3SBio Inc.) · Phase 1, Interventional, and Other

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a randomized, double-blind, placebo-controlled, single ascending dose phase I clinical study to evaluate the safety, tolerability, PK, PD and immunogenicity of SSS68 in healthy adult participants following a single subcutaneous administration.

Read the detailed description

This is the first-in-human (FIH) clinical study of SSS68. Seven dose groups are planned for dose escalation in this study: 2 mg, 50 mg, 200 mg, 400 mg, 600 mg, 900 mg and 1200 mg. The study will be conducted sequentially from low dose to high dose. Participants in all dose groups will receive a single subcutaneous injection.

The study consists of a screening period (no more than 4 weeks), a single-dose administration period (Day1), and a follow-up period (Day2 to Day113), with duration of approximately 20 weeks.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Shenyang Sunshine Pharmaceutical Co., LTD. is the lead sponsor of 40 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand and comply with protocol requirements, voluntarily participate in the trial and sign a written form (ICF).
  2. Male or female participants aged 18-45 years (inclusive) when signing the ICF.
  3. Male participants with body weight ≥ 50 kg, and female participants with body weight ≥ 45 kg.
  4. Participants whose vital signs, physical examination results, laboratory test results, 12-lead (ECG) and other test results are normal, or abnormal without clinical significance as determined by the investigator.
  5. IgG/IgM/IgA > value at the screening Visit.
  6. Female participants with and male participants (and their female partners) must agree to take highly effective measures and have no plan of childbearing, sperm donation, or egg donation from screening through at least 6 months after the dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. History of severe allergy, or with a history of allergy to the drug, any of its components, or related .
  2. With any diseases (including but not limited to gastrointestinal, hepatic, renal, neurological, hematological, endocrine, tumor, pulmonary, immunological, psychiatric, or cardiovascular diseases) prior to the screening visit.
  3. Had any confirmed or suspected or immune-deficient condition, including but not limited to history of opportunistic infections, asplenia, or primary immunodeficiency.
  4. History of recurrent or chronic infections, or any infection requiring hospitalization or intravenous antiviral/antibiotic treatment within 6 months before dosing.
  5. Participants with positive test results for surface antigen (HBsAg), anti- virus (HCV) antibody, anti- (HIV) antibody.
  6. Participants who have undergone major surgery within 6 months before dosing, or plan to undergo major surgery during the study.
  7. Participants who have received any marketed or investigational biological agent within 5 half-lives or 12 weeks (whichever is longer) before dosing.
  8. Participants who have used any prescription drugs, over-the-counter medications, vitamin supplements, or herbal products within 4 weeks or 5 half-lives (whichever is longer) before dosing.
  9. Participants who smoke more than 5 cigarettes per day within 3 months prior to screening.
  10. History of significant alcohol abuse or regular use of alcohol within 6 months prior to the screening visit.
  11. History of significant drug abuse, or any use of soft drugs within 3 months prior to screening, or any use of hard drugs within 1 year prior to screening, or positive result for urine drug screen test at screening.
  12. Participants who have been vaccinated with live or within 30 days before dosing, or plan to receive vaccination during the study.
  13. Participation in another interventional clinical trial within 3 months prior to screening.
  14. Participants who have donated blood (≥ 400 mL) or lost a lot of blood (≥ 400 mL) within 3 months before screening.
  15. ≥450 ms at the screening visit.
  16. Participants who have other factors making participation in this trial inappropriate, as judged by the investigator.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    SSS68

    SSS68 at doses ranging from 2 mg up to 1200 mg

    Drug: SSS68

  • Placebo comparator
    Placebo

    Matching placebo

    Drug: Placebo

Interventions

  • DrugSSS68

    A single dose of SSS68 will be administered SC on Day 1.

  • DrugPlacebo

    A single dose of placebo will be administered SC on Day 1.

06

What researchers measure

Primary outcomes

  1. Overall Summary of Treatment Emergent Adverse Events

    The number of adverse events (AEs), serious adverse events (SAEs), and drug related adverse events following administration of SSS68.

    Time frame: Baseline to day 113

Secondary outcomes

  1. Maximum Observed Serum Concentration (Cmax)

    The Cmax is the maximum observed serum concentration.

    Time frame: 0, 2, 6, and 12 hours post-dose, Day 2, 3, 4, 6, 8, 15, 22, 29, 43, 57, 85, and 113

  2. Time to Reach Maximum Observed Serum Concentration (Tmax)

    The Tmax is the time correspondent to the maximum observed serum concentration.

    Time frame: 0, 2, 6, and 12 hours post-dose, Day 2, 3, 4, 6, 8, 15, 22, 29, 43, 57, 85, and 113

  3. Terminal half-life (t1/2)

    The t1/2 is the time measured for the serum concentration to decrease by 1 half to its original concentration.

    Time frame: 0, 2, 6, and 12 hours post-dose, Day 2, 3, 4, 6, 8, 15, 22, 29, 43, 57, 85, and 113

  4. Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC[0-t])

    The AUC(0-t) is the area under the serum concentration-time curve from time 0 to last quantifiable concentration.

    Time frame: 0, 2, 6, and 12 hours post-dose, Day 2, 3, 4, 6, 8, 15, 22, 29, 43, 57, 85, and 113

  5. Area Under the Serum Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-inf])

    The AUC(0-inf) is the area under the serum concentration-time curve from time zero to infinite time.

    Time frame: 0, 2, 6, and 12 hours post-dose, Day 2, 3, 4, 6, 8, 15, 22, 29, 43, 57, 85, and 113

  6. Apparent Total Systemic Clearance (CL/F)

    The CL/F is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

    Time frame: 0, 2, 6, and 12 hours post-dose, Day 2, 3, 4, 6, 8, 15, 22, 29, 43, 57, 85, and 113

  7. Apparent Volume of Distribution (Vz/F)

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. The Vz/F after subcutaneous dose is influenced by the fraction absorbed.

    Time frame: 0, 2, 6, and 12 hours post-dose, Day 2, 3, 4, 6, 8, 15, 22, 29, 43, 57, 85, and 113

  8. Immunogenicity

    The number of participants with antibodies to SSS68.

    Time frame: Day 0, 15, 29, 57, and 113

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07606976
Responsible party
Sponsor
First posted
May 26, 2026
Start date
Jun 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion